share_log

Bristol-Myers Squibb | 4: Statement of changes in beneficial ownership of securities-Officer Plenge Robert M

SEC announcement ·  Mar 12 21:24
Summary by Moomoo AI
On March 10, 2024, Robert M. Plenge, EVP and Chief Research Officer at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Plenge acquired a total of 9,143 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 4,754 shares, with a portion of the disposals (2,965 shares) used to cover exercise prices or tax liabilities at an average price of $53.79 per share, amounting to a total market value of $105,697.35. After these transactions, Plenge directly held 11,315 shares of Bristol-Myers Squibb. Additionally, he indirectly held 1,856.842 shares through a savings and investment program and a family trust.
On March 10, 2024, Robert M. Plenge, EVP and Chief Research Officer at Bristol-Myers Squibb (BMY), completed a series of transactions involving the company's common stock. Plenge acquired a total of 9,143 shares through the exercise or conversion of derivative securities at no cost. Concurrently, he disposed of 4,754 shares, with a portion of the disposals (2,965 shares) used to cover exercise prices or tax liabilities at an average price of $53.79 per share, amounting to a total market value of $105,697.35. After these transactions, Plenge directly held 11,315 shares of Bristol-Myers Squibb. Additionally, he indirectly held 1,856.842 shares through a savings and investment program and a family trust.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more